摘要
目的:探讨门冬胰岛素30与口服降糖药治疗2型糖尿病的经济效果。方法:采用回顾性研究方法,选择165例2型糖尿病患者,随机分为3组(A组:门冬胰岛素30;B组:二甲双胍肠溶胶囊+格列美脲片+阿卡波糖片;C组:二甲双胍片+格列美脲片+瑞格列奈片)进行评价。结果:A、B、C 3组成本分别为140.80,141.82,251.72元,总有效率分别为87.93%,79.25%,83.33%(P>0.05),成本-效果比分别为1.60,1.79,3.02。结论:A组优于B和C组。
Objective： To evaluate the cost-effectiveness of NovoMix30FlexPen （Insulin-aspartate30） vs. oral hypoglycemic drugs on Type 2 diabetes meilitus. Method： A retrospective study was conducted in which a total of 165 cases with type 2 diabetes meilitus were devided into 3 group by random（ A ： NovoMix30FlexPen ; B ： Mefformin Hydrochloride Enteric-coated Capsules ＋ Glimepiride Tab- lets ＋ Acarbose Tablets ; C ： Mefformin Hydrocldoride Tablets ＋ Glimepiride Tablets ＋ Repaglinide Tablets） to be compared. Result： The cost was 140. 80 yuan in Group A versus 141.82 yuan in Group B vs. 251, 72 yuan in Group C; the total effective rates were 87. 93% versus 79. 25% versus 83.33% （P 〉0. 05） and the cost-effectiveness ratios were 1.60,1.79 and 3.02 respectively. Conclusion： Group A is superior to B and C groups for type 2 diabetes mellitus.
出处
《中国药师》
CAS
2010年第3期413-414,共2页
China Pharmacist
关键词
门冬胰岛素30
口服降糖药
2型糖尿病
成本-效果分析
Novo3OFlexPen
Oral hypoglyeemic drug
Type 2 diabetes mellitus
Cost-effectiveness analysis
